How does the NIH Stepwise approach apply to pediatric asthma management?

• A. Step 1 SABA PRN; Step 2 long-acting ICS; Step 3 high-dose ICS + LABA; Step 4 ICS with additional therapies
• B. Step 1 SABA PRN; Step 2 low-dose ICS; Step 3 low-dose ICS + LABA or medium-dose ICS; Step 4 high-dose ICS + LABA; Step 5 ICS with additional therapies or biologics
• C. Step 1 ICS; Step 2 SABA PRN; Step 3 Systemic steroids
• D. Step 1 IL-4 inhibitors; Step 2 IL-5 inhibitors

Answer: (B)

The main idea here is that pediatric asthma is managed with a stepwise, controller-focused strategy. Treatment starts with a rescue inhaler for quick relief, then adds a daily controller medication and gradually increases intensity only as needed to achieve control. In children, inhaled corticosteroids are the foundational controller therapy, and a long-acting beta-agonist is added to the ICS when symptoms persist, with the option to move to higher-dose ICS and LABA if control remains inadequate. If control continues to be poor, more advanced options such as additional add-ons or biologic therapies are considered for severe persistent asthma.

This progression—starting with rescue inhaler, then low-dose inhaled corticosteroids, then adding LABA or increasing to a medium-dose ICS, followed by high-dose ICS plus LABA, and finally considering add-on therapies or biologics—reflects the NIH Stepwise approach appropriately for pediatric patients. Other patterns either misplace or mischaracterize components (for example, using a nonstandard “long-acting ICS,” skipping ICS entirely, or escalating to systemic steroids or biologics too early), which is why they don’t fit the recommended framework.